Argos Therapeutics argostherapeutics.com


Public list: Pharma Startups (4743) Cancer Therapeutics (1148)

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis technology platform. Using biological co...Show all

Company (Acquired)

Phone: 919-287-6300

Fax:

4233 Technology Dr

Durham, 27704
North Carolina, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Argos Therapeutics $195.1M Feb 13, 2019
See all 58 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Argos Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Aurora FundsVenture CapitalDurham, North Carolina, United StatesSeries E - II, Series E, Series D, Debt - III, Debt - II, Series B, Unattributed VC
BD VenturesCorporate VentureFranklin Lakes, New Jersey, United StatesDebt - II, Series B, Unattributed VC
AAC Capital PartnersAsset/Investment ManagementAmsterdam, NetherlandsDebt - II
Aurora Capital GroupPrivate EquityLos Angeles, California, United StatesSeries C - II, Series C
Abenex CapitalPrivate EquityParis, FranceSeries B
See all 40 investors

Competitors

Company Status Description Investors
See all 58 competitors